Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
85.63
-1.54 (-1.77%)
Real-time:   3:06PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 85.45 - 86.99
52 week 81.89 - 123.37
Open 86.66
Vol / Avg. 7.21M/11.15M
Mkt cap 113.61B
P/E 7.33
Div/yield 0.47/2.20
EPS 11.69
Shares 1.35B
Beta 1.07
Inst. own 86%
Jul 26, 2016
Q2 2016 Gilead Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 7, 2016
Gilead Sciences Inc at Jefferies Healthcare Conference Add to calendar
May 23, 2016
Gilead Sciences Inc at UBS Global Healthcare Conference - 9:30AM EDT - Add to calendar
May 11, 2016
Gilead Sciences Inc Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
May 10, 2016
Gilead Sciences Inc at Bank of America Merrill Lynch Health Care Conference - 4:00PM EDT - Add to calendar
May 5, 2016
Gilead Sciences Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
Apr 28, 2016
Q1 2016 Gilead Sciences Inc Earnings Call - Webcast
Apr 28, 2016
Q1 2016 Gilead Sciences Inc Earnings Release
Mar 15, 2016
Gilead Sciences Inc at Barclays Global Healthcare Conference
Mar 7, 2016
Gilead Sciences Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 45.77% 55.47%
Operating margin 59.67% 68.00%
EBITD margin - 71.14%
Return on average assets 28.73% 41.86%
Return on average equity 87.88% 106.64%
Employees 8,000 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, cardiovascular, hematology/oncology and inflammation/respiratory. The Company's HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. The Company oncology product is Zydelig. The Company's respiratory products include Cayston and Tamiflu. The Company's other products include AmBisome and Macugen.

Officers and directors

John C. Martin Ph.D. Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Kathleen Watson Executive Vice President - Human Resources
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul Rutherford Carter Executive Vice President - Commercial Operations
Age: 55
Bio & Compensation  - Reuters
John F. Cogan Jr. Ph.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Etienne F. Davignon Independent Director
Age: 83
Bio & Compensation  - Reuters
Carla A. Hills Independent Director
Age: 81
Bio & Compensation  - Reuters